REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Dec 21, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-12-19

Reporting Person: YANCOPOULOS GEORGE (Director, EVP CSO Pres Regen Res Labs)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-12-19	Common Stock	M	5952.0	$16.8	Acquired	1072436.0	Direct
2012-12-19	Common Stock	M	4562.0	$21.92	Acquired	1076998.0	Direct
2012-12-19	Common Stock	M	4921.0	$20.32	Acquired	1081919.0	Direct
2012-12-19	Common Stock	M	17182.0	$11.64	Acquired	1099101.0	Direct
2012-12-19	Common Stock	M	10537.0	$9.49	Acquired	1109638.0	Direct
2012-12-19	Common Stock	M	7692.0	$13.0	Acquired	1117330.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-12-19	Incentive Stock Option (right to buy)	$9.49	M	10537.0	Disposed	2014-12-15	Common Stock (10537.0)	Direct
2012-12-19	Incentive Stock Option (right to buy)	$11.64	M	17182.0	Disposed	2015-12-19	Common Stock (17182.0)	Direct
2012-12-19	Incentive Stock Option (right to buy)	$13.0	M	7692.0	Disposed	2013-12-15	Common Stock (7692.0)	Direct
2012-12-19	Incentive Stock Option (right to buy)	$16.8	M	5952.0	Disposed	2018-12-17	Common Stock (5952.0)	Direct
2012-12-19	Incentive Stock Option (right to buy)	$20.32	M	4921.0	Disposed	2016-12-18	Common Stock (4921.0)	Direct
2012-12-19	Incentive Stock Option (right to buy)	$21.92	M	4562.0	Disposed	2017-12-17	Common Stock (4562.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5534.0	Indirect

Footnotes

F1: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F2: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.